Cowen Starts Loxo Oncology (LOXO) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Stifel Nicolaus Starts Loxo Oncology (LOXO) at Buy
September 2, 2014 6:54 AM EDTStifel Nicolaus initiated coverage on Loxo Oncology (NASDAQ: LOXO) with a Buy rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Loxo Oncology click here. For more ratings news on Loxo Oncology click here.
Shares of Loxo Oncology closed at $13.01 yesterday.
... MoreOppenheimer Starts Loxo Oncology (LOXO) at Outperform
September 2, 2014 6:28 AM EDTOppenheimer initiates coverage on Loxo Oncology (NASDAQ: LOXO) with a Outperform rating and a price target of $20.00.
Analyst Yigal Nochomovitz, Ph.D. commented, "Loxo is an early-stage biotechnology company executing a business plan for targeted cancer drugs that benefits from 1) clear precedent for... More
